SYNTHOS RESEARCH

CME Group CME

Financial Services · Financial - Data & Stock Exchanges · Synthos Deep Dive · 2026-08-04

$285.80
Buy — Tactical
—
—

The Overview

CME Group runs the world's biggest marketplace for futures contracts — agreements to buy or sell interest rates, stock indexes, currencies, oil, gas, grain, gold and copper at a future date. It also runs the clearing house that stands behind every trade and guarantees that both sides get paid.

That second part is the business. Because CME both matches the trades and guarantees them, a position opened at CME has to be closed at CME. You cannot take it somewhere cheaper. That is why CME has kept roughly 90% of the US interest-rate futures market for decades, and why it earns 65 cents of operating profit on every dollar of revenue — a margin almost no other public company achieves.

It also has more cash than debt, the lowest share-price volatility of any company in this batch, and it pays out essentially all of its profits as dividends: $11.25 per share over the last year, a 4.28% yield.

So why are the shares 20% below their high and down 6% over the past year while the market rose 24%?

One reason. A new kind of contract called a perpetual future, which grew up in crypto trading, works differently. In a normal futures market the clearing house guarantees settlement, which means it must collect enough margin to cover losses. In a perpetual market, a losing trader can only lose the money they put up, and if things go badly the exchange automatically closes positions rather than chasing anyone for more. That lets those venues offer far more leverage than CME can.

Our research library contains both views, and they are recent. One commentator, in June, said the selloff was "way overdone" and that he wanted to buy CME because "it's the king." Another — with the highest skill rating in that part of our library — said in March that traditional guaranteed-settlement clearing simply "can't compete."

The evidence so far is genuinely mixed. Over the first six months of this year, the number of contracts CME traded per day rose 10%. But in the second quarter alone it fell 1%, with interest-rate contracts down 6% and energy down 13%. CME says that is because markets got calmer after a turbulent start to the year, not because it lost customers. That is plausible and it is not proven.

At $262.63 the shares cost about 20 times what analysts expect the company to earn in 2027. Our estimate of fair value is $297, about 13% above the price, and you collect a 4.28% dividend while you wait. Analysts on average say $304 — but five of the thirty-seven covering the stock rate it a sell, which is the most negative view of any company in this batch.

That is why our rating is a Buy — but a tactical one: a superb business at a discount, with one genuine unanswered question about its future.

Putting a number on it: our fair-value estimate is $297 against a current price of $285.80 — real upside if our numbers are right.

Target entry zone $279 – $286 accumulate in this band; ideal adds on a dip toward the 200-day average near $279, keeping roughly a 4% margin below our $297 base-case fair value

Our summary metrics

Downside Risk (lower = safer)6/10High

"Rated 6 — an exceptionally high-quality business facing one genuine structural question, at a price that has already discounted part of it. The supports are unusual in this batch: a 64.9% operating margin and a 62.0% net margin; NET CASH, with `netDebt` of MINUS $666.2 million; interest coverage of 50.3x; a 4.28% dividend yield; and a beta of 0.276 — by a wide margin the lowest in this batch, against Freeport's 1.364 and KKR's 1.794. Vertically integrated clearing plus the non-fungibility of futures positions means open interest cannot be moved to a competing venue, which is the single most durable moat in exchange businesses. Against that, five risks. FIRST and structurally largest, perpetual futures: the knowledge base's highest-skill voice argues directly that 'guaranteed-settlement TradFi clearing can't compete' with the perpetual model's margin-and-auto-deleveraging design, and the market agrees enough to have taken 19.6% off the share price. SECOND, the volume evidence is now two-sided: June-quarter average daily volume FELL 1% to 29,843 thousand contracts, with interest rates down 6% and energy down 13%, against six-month volume up 10%. THIRD, the payout ratio is 95.4% — CME's variable annual dividend distributes essentially all of earnings, so the 4.28% yield falls with earnings and there is no retained buffer. FOURTH, tangible book value is NEGATIVE $3.41 per share, because $30,300.7 million of goodwill and intangibles from the CBOT, NYMEX and COMEX acquisitions exceeds $28,728.2 million of equity. FIFTH, five of thirty-seven covering analysts have SELL ratings and the vendor consensus is Hold — the most negative sentiment distribution in this batch."

Growth Quality5/10Moderate

"Rated 5 — high-quality, slow, and volatility-dependent. Revenue: $5,019.4M (FY2022), $5,578.9M (FY2023), $6,130.1M (FY2024), $6,520.6M (FY2025) — 11.1%, 9.9%, 6.4%. Adjusted EPS from the `earn_cal` actuals runs $2.96, $2.68, $2.77, $3.36 and $2.99 across the last five quarters — a trailing $11.80 — with beats of 1.7%, 1.9%, 0.7%, 0.6% and 2.7%. FIVE CONSECUTIVE BEATS, every one of them small: this is the most precisely-modelled company in this batch, which is what a fee-per-contract business with published daily volumes looks like. Consensus wants $12.254 in FY2026 (9 analysts), $12.924 in FY2027 (10) and $13.865 in FY2028 (4) — 9.6%, 5.5%, 7.3%. The volume detail from the June-quarter 10-Q shows exactly where growth comes from and where it does not: six-month average daily volume up 10% to 33,011 thousand contracts, with metals up 56%, energy up 11%, equity indexes up 10% and interest rates up 9%, against foreign exchange down 3%. The company's own explanation of the June quarter's 1% decline is that 'overall market volatility subsided relative to periods of very high volatility earlier in the year' following the early-2026 Middle East conflict. What holds this at 5: 5.5% consensus earnings growth in FY2027 is slow, roughly half of it is pricing rather than volume, and the volume half is a bet on the world remaining volatile — which is a real bet and not a growth strategy."

Exponential Potential4/10Moderate

"Rated 4 — a genuinely rare moat attached to a business that grows at nominal GDP plus volatility. The moat is well described by the knowledge base's single distilled analysis: vertically integrated clearing plus the non-fungibility of futures contracts means a position opened at CME must be closed at CME, so liquidity cannot migrate the way it can in fungible cash equities; CME holds roughly 90% of US interest-rate futures; and it captures a tiny fraction of contract value relative to the tick size, giving latent pricing power that can be used without materially affecting users. Six asset classes — interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — buffer earnings across cycles and permit cross-margin collateral offsets that deepen client lock-in. The structural growth is real but bounded: rising Treasury issuance mechanically expands the rate-futures pool; international benchmarking to WTI and Henry Hub expands energy; and a more volatile world raises turnover. The genuine optionality is elsewhere: regulated prediction markets, where the knowledge base notes CME alongside Kalshi and Polymarket's regulated venue, and crypto derivatives, where CME futures are already the institutional benchmark. Against all of it, the same structure that protects CME also caps it — a clearing house guaranteeing settlement must hold margin, and the perpetual-futures model that lets a loser lose only their margin can offer leverage CME cannot. A 4: a superb, defensible, low-growth franchise with one credible technological attacker."

Fair value$297 $207–$360
What does “fair value” mean?

Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.

The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.

What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

The Road Ahead

What we expect to matter in each window, and the evidence that would prove us wrong.

Short term 0-6 months

Neutral
Driver
"A quality asset recovering off a competition-driven selloff, with the recovery already 20% old and RSI at the top of this batch. CME closed 2026-08-04 at $262.63, down 1.33%, which is 19.6% below its 52-week high of $326.46 and 20.2% above its low of $218.58, 4.3% above a 50-day average of $251.80 but 5.7% BELOW a 200-day average of $278.52. RSI is 69.1 — the highest reading in this batch and close to overbought — and MACD is +4.79. Relative performance is poor across every window: 3-month MINUS 9.5% against SPY's +7.6%, 6-month MINUS 9.7% against +11.1%, 12-month MINUS 6.5% against +24.3%. The maximum drawdown from peak over the year is 19.6%. The cause is identifiable: the knowledge base records CME's 'biggest weekly drop since 2020' on perpetual-futures fears alongside Cboe down 8% and ICE. The stock has since recovered 20% off the low, which is why RSI is at 69 and why the stance is neutral rather than a tailwind — the easy part of the bounce is behind, and the structural question is not resolved. Underneath, the operating evidence is mixed: five consecutive earnings beats, but June-quarter average daily volume DOWN 1%."
What we’re watching
"The 2026-10-28 print against consensus adjusted EPS of $2.96 and revenue of $1,697M — a forecast of a 1.0% EPS DECLINE and a 0.5% revenue decline against the June quarter, which is itself informative. Within it, the number that settles the debate: aggregate average daily volume, 29,843 thousand contracts in the June quarter against 30,217 a year earlier, DOWN 1%. Two sub-lines matter more than the total — interest rates, down 6% to 14,532 thousand and roughly half of all volume, and energy, down 13% to 2,667 thousand. If those decline again while equity indexes keep growing, the mix question becomes a share question. Also watch the average rate per contract, which the 10-Q discusses as the other half of clearing and transaction fee revenue and which is where any competitive price pressure would first appear. Separately: the leadership transition — Terrence A. Duffy moves to Executive Chairman and Lynne C. Fitzpatrick becomes chief executive under agreements dated 2026-06-16 — and whether the strategy on perpetual-style products or 24/7 trading changes under her."
Confidence
Medium

Medium term 6-24 months

Tailwind
Driver
"The medium-term case is a monopoly-like cash machine bought at a discount to its own history because of a competitive threat that has not yet appeared in the numbers. Consensus has adjusted EPS at $12.254 in FY2026, $12.924 in FY2027 and $13.865 in FY2028 — 9.6%, 5.5%, 7.3% — on revenue rising from $6,520.6M actual to $7,029M, $7,383M and $7,861M. That is slow, and it is paired with a 4.28% dividend yield that does a great deal of the work: at a 95.4% payout ratio CME distributes essentially all its earnings, and the total shareholder yield of roughly 4.6% plus 5.5% earnings growth is a 10% return before any multiple change. The multiple is where the opportunity is. At 20.3x FY2027 the stock sits below the low-to-mid twenties this franchise has generally commanded, and the gap is attributable to a specific, dated, identifiable fear rather than to deterioration. The structural supports are intact and filing-verified: six-month volume up 10%, metals up 56%, energy up 11%, equity indexes up 10%, interest rates up 9%; a 64.9% operating margin; net cash; and roughly $1.1 billion a year of equity income from the 27%-owned S&P Dow Jones Indices venture, which is why pre-tax profit exceeds operating profit."
What we’re watching
"Whether perpetual futures take institutional share, and where it shows up. The mechanism the bear case describes is specific — a perpetual contract where the loser can only lose their posted margin, backed by auto-deleveraging rather than a guaranteed-settlement clearing house, can offer leverage a regulated clearer cannot. If that is right, it appears first in the fastest-growing, most retail-adjacent product lines, not in Treasury futures. Watch the crypto and equity-index complexes rather than the rate complex. Whether interest-rate volume, down 6% in the June quarter and roughly half the total, recovers with Treasury issuance as the knowledge base's structural claim predicts. Whether the average rate per contract holds — competitive pressure shows up in price before it shows up in volume. Whether the variable annual dividend is maintained; at a 95.4% payout it moves directly with earnings and it is roughly half the expected return. Whether the S&P Dow Jones Indices equity income keeps growing, now that the OSTTRA joint venture has been sold (fourth quarter of 2025) and no longer contributes. And whether Lynne Fitzpatrick, taking over from a chief executive who has run this company since 2002, changes the product strategy."
Confidence
Medium

Long term 2+ years

Neutral
Driver
"Long-run, CME owns the deepest liquidity pools in global interest-rate, equity-index and energy futures, and the physics of futures markets protect them: a contract opened at CME must be closed at CME, so liquidity does not migrate incrementally the way it can in fungible markets — it migrates all at once or not at all. That property has defended this franchise through four decades of attempted competition, and the knowledge base's structural analysis makes the case well: roughly 90% of US interest-rate futures, vertically integrated clearing, cross-margin offsets across six asset classes, and latent pricing power measured against tick size rather than against contract value. Growing Treasury issuance mechanically expands the addressable pool. Against that sits the one argument that has ever plausibly threatened this model, and the knowledge base contains it from its highest-skill voice: perpetual futures with margin-limited losses and auto-deleveraging are a different clearing architecture, not merely a different contract, and they can offer leverage a guaranteed-settlement clearer cannot. `raoul_pal` frames the general case — 'Order books tend toward monopoly unless acted upon, but markets repeatedly demand a competitor — Nasdaq to NYSE, ICE to CME, Bullish to Deribit.' The long-run stance is neutral because both arguments are coherent and the evidence to date does not separate them."
What we’re watching
"Whether any perpetual-style venue achieves institutional-scale open interest in a non-crypto asset class — that is the single event that would convert a narrative into a threat. Whether US regulators permit perpetual contracts on regulated venues, and whether CME launches its own; the knowledge base notes CME alongside Kalshi and Polymarket's regulated exchange in prediction markets, so the company is not absent from the adjacent frontier. Whether interest-rate futures volume tracks Treasury issuance as the structural claim assumes, or whether cash-market and swap alternatives take share. Whether the clearing-house model survives a genuine default event — CME's balance sheet carries $198.5 billion of assets, overwhelmingly member performance bonds and guaranty-fund contributions, and the whole franchise rests on that guarantee never failing. Whether the legacy Class B share structure, which retains the right to elect three directors and whose holders defeated a proposal to remove that right at the 2026 annual meeting, constrains strategic flexibility. And whether the leadership transition from Terrence A. Duffy — who has run this company since 2002 — to Lynne C. Fitzpatrick is a continuity appointment or a change of direction."
Confidence
Low

Exponential Potential

Exponential Potential4/10Moderate

"Rated 4 — a genuinely rare moat attached to a business that grows at nominal GDP plus volatility. The moat is well described by the knowledge base's single distilled analysis: vertically integrated clearing plus the non-fungibility of futures contracts means a position opened at CME must be closed at CME, so liquidity cannot migrate the way it can in fungible cash equities; CME holds roughly 90% of US interest-rate futures; and it captures a tiny fraction of contract value relative to the tick size, giving latent pricing power that can be used without materially affecting users. Six asset classes — interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — buffer earnings across cycles and permit cross-margin collateral offsets that deepen client lock-in. The structural growth is real but bounded: rising Treasury issuance mechanically expands the rate-futures pool; international benchmarking to WTI and Henry Hub expands energy; and a more volatile world raises turnover. The genuine optionality is elsewhere: regulated prediction markets, where the knowledge base notes CME alongside Kalshi and Polymarket's regulated venue, and crypto derivatives, where CME futures are already the institutional benchmark. Against all of it, the same structure that protects CME also caps it — a clearing house guaranteeing settlement must hold margin, and the perpetual-futures model that lets a loser lose only their margin can offer leverage CME cannot. A 4: a superb, defensible, low-growth franchise with one credible technological attacker."

What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.

Deeper analysis

Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.

Check our number Market-implied growth ≈ 17%/yr This isn’t how we calculate fair value — it’s public math you can verify yourself. To justify today’s $286, earnings would have to compound roughly 17% a year for 10 years (9% discount rate). Analysts forecast ~8%/yr, so the market is pricing in MORE than what the Street expects.

Reference table

Street consensus$304.33 (+15.9%) · median $309 (+17.7%) · high $330 (+25.6%) · low $260 (−1.0%) · 0 strong buy / 15 buy / 17 hold / 5 sell across 37 analysts — vendor consensus "Hold", and the most sell ratings in this batch
Valuation22.3x trailing adjusted EPS ($11.80) · 21.4x FY2026E $12.254 · 20.3x FY2027E $12.924 · 18.9x FY2028E $13.865 · 17.8x EV/EBITDA · 3.57x book
Margins — among the highest of any listed companyOperating margin 64.9% (FY2025) · net margin 62.0% · gross margin 81.9% · interest coverage 50.3x · net cash: netDebt MINUS $666.2M
Capital return — the dividend IS the return$11.25 TTM, a 4.28% yield, on a 95.4% payout ratio (a regular quarterly plus a variable annual) · buyback $266.1M in FY2025, 0.28% · total shareholder yield ≈ 4.6%
Volume — the number that decides thisSix months: aggregate ADV 33,011k contracts, +10% (metals +56%, energy +11%, equity indexes +10%, interest rates +9%, FX −3%) · June quarter: 29,843k, DOWN 1% (interest rates −6%, energy −13%, equity indexes +13%)
Not in the payloadLeadership transition: Terrence A. Duffy to Executive Chairman, Lynne C. Fitzpatrick to chief executive, under agreements dated 2026-06-16 · OSTTRA joint venture sold in Q4 2025 · a Class B-1 governance proposal defeated at the 2026 annual meeting
ConvictionModerate, bullish, severely concentrated — 27 raw KB hits, 5 used, 22 discarded. 14 discards are crypto claims using CME futures as a measuring instrument; 8 of 12 entity claims are one podcast episode dated 2025-08-17, collapsed to one
Technicals−19.6% from the 52-week high of $326.46; +20.2% above the low of $218.58; +4.3% above the 50-DMA ($251.80) but −5.7% BELOW the 200-DMA ($278.52); RSI 69.1 — the highest in this batch; MACD +4.79; 12-month −6.5% vs SPY +24.3%

What the experts actually said 12 traceable claims on CME · showing the highest-conviction voices

“Perps' edge is clearing, not product spec: loser-can-only-lose-margin + ADL lets exchanges offer real leverage; guaranteed-settlement TradFi clearing can't compete.”
Arthur Hayesbullishconviction 852026-03-05
“CME is best-in-class derivatives exchange with dominant liquidity and vertically integrated clearing; a durable, high-quality compounder.”
Business Breakdownsbullishconviction 852025-08-17business_breakdowns-GlNFrhxke3E:6f3f1e7dfc
“Exchange-stock selloff on perpetual-futures fears (CME biggest weekly drop since 2020, Cboe -8%, ICE) is way overdone; want to buy CME — it's the king.”
Compound And Friendsbullishconviction 682026-06-23
“Price discovery demonstrably happens on regulated CME futures; industry has satisfied surveillance-sharing and manipulation concerns.”
Real Visionbullishconviction 652022-09-12
“Institutions aren't really trading Bitcoin yet; if they were, regulated CME volumes would dwarf offshore exchanges since banks won't touch unlicensed startups.”
Arthur Hayesbearishconviction 752019-08-29

Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.

Price & moving averages 12 months · 50 & 200-day averages · 52-week range

210241273304335Aug '25Nov '25Jan '26Apr '26Jun '26Aug '2652w hi $326Price 286200-DMA 27950-DMA 25452w lo $219

Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.

Data summary: last close $285.80, 13% above the 50-day average ($254), 3% above the 200-day average ($279) — an uptrend. 12% below the 52-week high of $326, 31% above the 52-week low of $219.

Bollinger Bands 20-day average ± 2 standard deviations

202236270304338Aug '25Nov '25Jan '26Apr '26Jun '26Aug '26Price 28620-day avg 270

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

Data summary: price $285.80 is currently at/above the upper band (stretched) (band $255–$285).

RSI (14) momentum gauge · 0–100

705030Aug '25Nov '25Jan '26Apr '26Jun '26Aug '26RSI 71.7

Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 72.

MACD 12 / 26 / 9 · trend & momentum

0Aug '25Nov '25Jan '26Apr '26Jun '26Aug '26MACD 6.9signal 5.7

The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.

Data summary: MACD is currently above its signal line by 1.19, positive momentum.

Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago

7990102114126Aug '25Nov '25Jan '26Apr '26Jun '26Aug '26S&P 500 119XLF (sector) 108CME 107

Solid = CME · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

025710$6BFY23EPS $9$6BFY24EPS $10$7BFY25EPS $11$7BFY26EEPS $12$7BFY27EEPS $13$8BFY28EEPS $14$8BFY29EEPS $15$9BFY30EEPS $16

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$285.80
Market cap$103B
P/E trailing24×
P/E FY26E / FY27E23× / 22×
EV / Sales15.1×*
EV / EBITDA19.0×*
Gross margin81.9%
Net margin63.1%
Dividend yield3.94%
Beta0.267
52-wk range$219 – $326
RSI(14)73
50 / 200-DMA$254 / $279
12-mo return+6% (SPY +19%)
Street target$299 ($260–$330)
Analyst grades14 Buy · 18 Hold · 5 Sell
FMP ratingB+
Next earnings2026-10-28 (Q3 2026 earnings, 85 days away; vendor consensus adjusted EPS $2.96 and revenue $1,697M, implying a 1.0% EPS decline and a 0.5% revenue decline against the June quarter). Second-quarter results were released 2026-07-22, thirteen days before this dive, and beat consensus EPS by 2.7% ($2.99 against $2.91) on revenue of $1,706.2M against $1,682.1M estimated — the fifth consecutive beat.

* Enterprise value recomputed in-house: the data vendor nets cash but omits short-term investments, overstating EV for cash-rich balance sheets. EV multiples marked * use market cap + total debt − cash − short-term investments.

1. What the business is, and the volume evidence

CME Group is a Delaware-incorporated exchange holding company, Nasdaq-listed, with approximately 3,875 employees. Terrence A. Duffy has been chief executive since 2002 and is moving to Executive Chairman, with Lynne C. Fitzpatrick — currently President and Chief Financial Officer — taking over, under a Transition and Executive Chairman Agreement and an Employment Agreement both dated 2026-06-16. The 2026-07-22 results 8-K is already signed by Fitzpatrick.

Revenue by line, from seg_prod — and this block reconciles to the dollar:

FY2025RevenueshareFY2024growth
Clearing and transaction fees$5,281.1M81.0%$4,988.2M+5.9%
Market data$803.1M12.3%$710.2M+13.1%
Other revenue$436.4M6.7%$431.7M+1.1%
Sum$6,520.6M100.0%$6,130.1M+6.4%
inc_a FY2025 revenue$6,520.6M$6,130.1MEXACT

Both years reconcile exactly, and the split matches the knowledge base's structural description ("~$6B revenue, ~80% clearing/trading"). seg_geo is EMPTY — zero entries for any year.

The volume table — the most important data in this dive

From the 10-Q filed 2026-07-24, average daily contract volume in thousands:

Product lineQ2 2026Q2 2025changeH1 2026H1 2025change
Interest rates14,53215,472−6%16,58615,252+9%
Equity indexes8,6347,661+13%8,6447,827+10%
Foreign exchange9891,096−10%1,0911,123−3%
Energy2,6673,082−13%3,3202,993+11%
Agricultural commodities2,0801,964+6%2,0611,961+5%
Metals941942flat1,309838+56%
Aggregate29,84330,217−1%33,01129,994+10%
CME Globex27,93528,097−1%30,76127,916+10%
Open outcry830993−16%1,034938+10%
Electronic % of total94%93%—93%93%—

The company's own explanation, verbatim:

> "Overall market volatility was high in early 2026 due to the heightened geopolitical conflict in the Middle East... However, in the second quarter of 2026, overall market volatility subsided relative to periods of very high volatility earlier in the year as market uncertainty tapered. We believe these factors contributed to volume remaining relatively flat in the second quarter of 2026 when compared to the same period in 2025 and an increase in volume in the first six months of 2026 when compared with the same period in 2025."

Read that carefully, because it is the crux. A 1% decline in the quarter that the market is worried about competition is exactly the shape a competitive-share-loss story would take, and it is also exactly the shape a volatility-normalisation story would take. The six-month +10% figure supports management's explanation; the −6% in interest rates — half of all volume, and the product where CME's moat is supposedly strongest — is the number that does not. We report both and do not claim to resolve it. The 2026-10-28 print is the next observation.

One further structural note the payload does not explain. Pre-tax income of $5,330.5 million in FY2025 EXCEEDS operating income of $4,229.5 million, which is why pretaxProfitMarginTTM (82.6%) is above operatingProfitMarginTTM (65.1%) and ebtPerEbitTTM reads 1.269. The gap is equity income from the S&P Dow Jones Indices joint venture, of which CME owns a minority stake, and which the 10-Q says increased in the first six months of 2026. The same line fell in the second quarter "as a result of the sale of our OSTTRA joint venture which occurred in the fourth quarter of 2025" — a disposal that also explains the acquisitionsNet figure of POSITIVE $1,580.4 million in FY2025 (proceeds received, not consideration paid). Neither the OSTTRA sale nor its effect appears anywhere in the vendor payload.

2. Earnings — five consecutive small beats

Report dateQuarterRevenueAdjusted EPSestimatebeat
2025-07-23Q2 2025$1,692.0M$2.96$2.91+1.7%
2025-10-22Q3 2025$1,537.6M$2.68$2.63+1.9%
2026-02-04Q4 2025$1,648.7M$2.77$2.75+0.7%
2026-04-22Q1 2026$1,880.1M$3.36$3.34+0.6%
2026-07-22Q2 2026$1,706.2M$2.99$2.91+2.7%
2026-10-28Q3 2026—?$2.96—

Trailing four quarters: $2.68 + $2.77 + $3.36 + $2.99 = $11.80. At $262.63 that is 22.3x trailing, matching the vendor's priceToEarningsRatioTTM of 22.16x to within 0.6%.

Five consecutive beats, none larger than 2.7%. This is the most precisely-modelled company in this batch — which is what happens when a business publishes its volumes daily and charges a known rate per contract. earn_cal.revenueActual matches inc_q revenue to the dollar in all five quarters. The corollary is that there is almost no scope for a positive earnings surprise to re-rate this stock; the multiple will move on the competitive question, not on the print.

June-quarter revenue of $1,706.2M was +0.8% year on year against Q1's +14.5% — the same deceleration the volume table shows, and consistent with the volatility explanation.

The annual record:

Fiscal yearRevenuegrowthOperating incomeOperating marginNet incomeGAAP EPS
FY2022$5,019.4M—$3,015.9M60.1%$2,691.0M$7.41
FY2023$5,578.9M+11.1%$3,435.7M61.6%$3,226.2M$8.87
FY2024$6,130.1M+9.9%$3,931.5M64.1%$3,525.8M$9.69
FY2025$6,520.6M+6.4%$4,229.5M64.9%$4,044.4M$11.18

Revenue up 30% over three years, operating income up 40%, and the operating margin up 480 basis points to 64.9%. That is an exceptional record and it is the reason the competitive question matters so much: nothing else in this file is broken.

3. Valuation — priced in or room?

At $262.63 (market capitalisation $94.44B, implied 359.6M shares):

TrailingFY2026EFY2027EFY2028E
Adjusted EPS$11.80$12.254 (9)$12.924 (10)$13.865 (4)
Estimate range—$12.075–$12.604 (4.4%)$12.179–$13.337 (9.5%)$13.204–$14.274 (8.1%)
Growth—+9.6%+5.5%+7.3%
P/E22.3x21.4x20.3x18.9x
Revenue$6,520.6M (FY2025)$7,029M (11)$7,383M (11)$7,861M (8)
EV / EBITDA17.8x———
Net debt / EBITDANET CASH (−0.24x)———
Price / book3.57x———
Price / TANGIBLE bookNEGATIVE — see Section 4———
Dividend yield4.28%———
Payout ratio95.4%———

Estimate coverage is adequate on the near years and thin beyond. Nine analysts on FY2026 adjusted EPS, ten on FY2027, only 4 on FY2028 and 2 each on FY2029 and FY2030. FY2028 is used for cross-check only; FY2029 and FY2030 are excluded from every conclusion. The FY2027 range of $12.179 to $13.337 is 9.5% wide.

est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature AND are implausible in level — REJECTED. ebitdaAvg is exactly 91.275% of revenueAvg and ebitAvg exactly 89.735% in FY2026, FY2027, FY2028, FY2029 and FY2030 alike. A 91.3% EBITDA margin against the 79.2% the company actually reports on a trailing basis and the 64.9% operating margin it earned in fiscal 2025 is not a forecast; it is a formula. All forward valuation uses epsAvg, which is well validated: the FY2025 estimate of $11.174 against a reported GAAP EPS of $11.18 is a 0.05% difference.

Enterprise value is usable and small relative to market capitalisation because the company holds net cash. $95,716M against a market capitalisation of $94,436M. netDebt is MINUS $666.2 million. Noncontrolling interests are zero, so no NCI omission is possible. Finance lease obligations of $279.1M are included in total debt of $3,757.2M — no lease double-count.

Peer context is mixed and contains the two comparables that matter. The vendor set is Brookfield Asset Management, Bank of Montreal, Bank of Nova Scotia, Coinbase, ICICI Bank, Intercontinental Exchange, Moody's, Mizuho, Marsh & McLennan and Nasdaq. ICE ($83.7B) and Nasdaq ($52.3B) are the genuine exchange comparables, and Coinbase ($39.8B) is the crypto-native counterpart to precisely the competitive question at issue. Four banks, a ratings agency and an insurance broker are unrelated. No cross-multiple is drawn, though we note the knowledge base's own reference point: arthur_hayes (2026-06-12) cites "Hyperliquid... at ~20x earnings (circulating supply) vs Coinbase 60x, CME 25x."

3a. What today's price assumes (the inversion)

At $262.63 — 21.4x FY2026 consensus, 20.3x FY2027, 4.28% dividend yield — the price embeds:

3b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: adjusted EPS growth (+5.5%, from FY2026E $12.254 to FY2027E $12.924) + multiple EXPANSION (20.3x on the forward year toward roughly 23x, +13%) + shareholder yield (+4.6%: a 4.28% dividend and a 0.28% buyback) ≈ +18% to +20% on a total-return basis, of which our $297 base captures the price component.

This dive's base case DOES require modest multiple expansion, and we flag it rather than bury it. If the multiple simply holds at 20.3x on the FY2027 number, the price is $262 — spot — and the return is the 4.6% shareholder yield alone. That is not a disaster and it is not the case being made. The case is that 20.3x is a competition discount applied to a franchise whose competitive position has not yet measurably changed, and that as the volume data resolves, the discount narrows.

Note the composition, and it is the reason this clears the Tactical bar where a similar-looking name might not: roughly a quarter of the expected return is a 4.28% dividend that requires nobody to change their mind. Compare KKR elsewhere in this batch — a similar base-case return with a shareholder yield under 1%, so the entire outcome depends on the re-rating. Here it does not.

If the multiple fell to 17x FY2027E the price is $220 (−16.2%). If it expanded back to 25.3x — where the stock traded within the last year — $327 (+24.5%).

3c. Variant perception (where we differ, what would surprise)

Synthos fair values

All three anchors are multiples of the FY2027 consensus adjusted EPS distribution (mean $12.924, low $12.179, high $13.337, 10 analysts).

Base is 13.1% above spot; price asymmetry roughly 1.75:1 (21.2% down, 37.1% up). Including the 4.28% dividend, base total return is approximately +17.4%, bear approximately −17%, bull approximately +41% — a total-return payoff ratio near 2.4:1. A base above 13%, a total-return payoff above 2:1, roughly a quarter of the return delivered as a dividend that requires nobody to change their mind, and a 0.276 beta, is what the Buy — Tactical tier exists for. What keeps it out of Core is Section 6.

4. Data integrity — what we rejected and why

Eight findings. Two blocks passed tests that have failed repeatedly elsewhere, including the specific gross-up test this name was flagged for.

1. THE GROSS-UP TEST — RUN, AND PASSED CLEANLY. The brief identified USB, KKR and CME as prime candidates for the revenue-gross-up defect that turned Capital One's $53.4 billion into $69.3 billion and IBKR's $6.1 billion into $10.2 billion. CME passes on four independent checks. inc_a FY2025 revenue of $6,520.6M matches est.revenueAvg for the same year ($6,518.9M) to within 0.03%; seg_prod sums to $6,520.6M exactly; the four fiscal-2025 quarterly revenues in inc_q sum to $6,520.6M exactly; and earn_cal.revenueActual matches inc_q revenue to the dollar in all five reported quarters. CME's revenue is reported net, consistently, in every block of the payload. This is a clean result and it is recorded as one — the other two flagged names did not fare as well (USB's line is a 50.2% gross-up; KKR's estimates sit on a segment basis 2.4x below its GAAP revenue).

2. est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature and are implausible in level — REJECTED. ebitdaAvg is exactly 91.275% of revenueAvg and ebitAvg exactly 89.735% in five consecutive forward years. A 91.3% EBITDA margin for a company reporting a 79.2% trailing EBITDA margin and a 64.9% operating margin is not merely fabricated but materially optimistic. All forward valuation uses epsAvg, validated at 0.05% against the FY2025 actual.

3. inc_q for the June 2026 quarter reports EBITDA BELOW operating income and a NEGATIVE interest expense — two impossibilities in one row. The quarter shows operatingIncome of $1,107.1M and ebitda of $834.4M — EBITDA cannot be lower than operating income for a company with depreciation. It also shows interestExpense of MINUS $43.6M, where every one of the eight other quarters reports a positive $40-44M. The sign is inverted and the EBITDA figure is derived from it. ebitda for the June quarter is not used; the annual figure and the operating-income line, which matches the pattern of the other quarters, are.

4. The balance sheet is 85% customer collateral, so every asset-based ratio is an artefact — REJECTED as a class. Total assets are $198,548.4M against total equity of $28,728.2M; the difference is overwhelmingly clearing-member performance bonds and guaranty-fund contributions, which are customer property held by the clearing house. Consequently returnOnAssetsTTM of 2.19%, assetTurnoverTTM of 0.0348, financialLeverageRatioTTM of 7.34x, debtToAssetsRatioTTM of 1.76%, solvencyRatioTTM of 2.64%, operatingCashFlowRatioTTM of 0.027 and cashRatioTTM of 0.0135 are all measuring the wrong denominator and none is used. The measures used are the operating margin (64.9%), return on equity (15.5%), return on capital employed (12.3%) and net debt (net cash).

5. The current-asset and current-liability classification CHANGES between fiscal 2024 and fiscal 2025 by roughly $100 billion. totalCurrentAssets goes from $103,033.5M (FY2024) to $5,187.6M (FY2025), and totalCurrentLiabilities from $102,313.9M to $55.8M — a 99.9% fall in each. The clearing collateral was classified as current in one year and not in the next. currentRatioTTM of 1.018 and quickRatioTTM of 1.018 are therefore not comparable across years and are not used. Note the same effect flows into cf_a: netChangeInCash reads +$62,285.4M in FY2025, −$44,864.6M in FY2023 and −$22,815.5M in FY2022 — clearing-member cash movements, not corporate cash flow.

6. tangibleBookValuePerShareTTM is NEGATIVE $3.413 — and this is a real feature, not an error. Goodwill of $10,514.7M plus intangible assets of $19,786.0M totals $30,300.7M against total equity of $28,728.2M, so tangible book is negative by $1,228.7M (tangibleAssetValueTTM). That is the accumulated purchase accounting from the CBOT, NYMEX and COMEX acquisitions, and it means no tangible-book cross-check is available for this name. priceToBookRatioTTM of 3.565x on reported book is used instead, with the caveat that a book value 105% composed of intangibles is a weak anchor.

7. seg_geo is EMPTY — zero entries for any year. There is no geographic revenue disclosure for CME in the payload at all, for a company that describes itself as operating "international marketplaces." Reported as empty rather than substituted.

8. acquisitionsNet reads POSITIVE $1,580.4 million for fiscal 2025 and is a DISPOSAL, not an acquisition. The 10-Q explains it: equity income fell in the second quarter of 2026 "as a result of the sale of our OSTTRA joint venture which occurred in the fourth quarter of 2025." A reader treating the positive figure as acquisition spend would conclude CME was a net buyer of businesses in a year in which it was a seller. This is the same defect class as Capital One's +$16,465M acquisitionsNet in the year of the Discover merger.

Also checked and recorded — and the segment and calendar blocks are clean. seg_prod reconciles to the reported revenue line EXACTLY in both fiscal 2025 and fiscal 2024. inc_q passed the MO/APP two-basis test — nine quarters on one basis, the four fiscal-2025 quarters summing to $6,520.6M exactly matching inc_a. earn_cal passed the SPGI mixed-basis test — all five actual-versus-estimate pairs on the adjusted basis, with revenueActual matching inc_q to the dollar in every case. quote.yearHigh/yearLow ($329.16 / $218.31) against tech.hi52/lo52 ($326.46 / $218.58) — a 0.8% and 0.1% discrepancy; tech is used throughout. effectiveTaxRateTTM of 23.6% is consistent with FY2025's incomeTaxExpense of $1,273.2M on incomeBeforeTax of $5,330.5M (23.9%). The implied share count (359.6M) is consistent with revenuePerShareTTM and with the 8-K's 362,808,081 Class A and B shares issued and outstanding at the 2026-03-16 record date.

returnOnEquityTTM — source stated. Present in km_ttm at 15.53% and absent from ratios_ttm. Used as reported; note the equity base is inflated by $30.3 billion of acquisition intangibles, so return on tangible capital is far higher and is not computable from this file because tangible equity is negative.

Vendor composite rating — noted, low weight. B+ / 3 overall, with 4 out of 5 on discounted cash flow, return on equity, return on assets and debt-to-equity, and 1 out of 5 on price-to-book. The return-on-assets sub-score is struck on the clearing-collateral denominator rejected in finding 4, and the price-to-book score of 1 penalises a company whose book value is 105% intangibles. Neither carries weight.

Non-equity tripwire — checked and passed, with a governance note. CME is Class A common stock, Nasdaq-listed. Price of $262.63 is not par-like; beta is 0.276 — the lowest in this batch by a wide margin; volume was 1.96M shares (~$515M of turnover); the 52-week band of $218.58 to $326.46 is a 49% range. Note the legacy Class B-1, B-2 and B-3 common stock held by former exchange members, which carries the right to elect three directors: the 2026 annual meeting lacked a quorum among those classes on 14 May and had to be adjourned to 9 June, and a proposal to eliminate the Class B-1 director-election right DID NOT PASS. Those are not this security. This is common equity.

5. Knowledge base — twenty-seven hits, five used, and the sweep exposed two distinct defects

Raw hits: 27. Entity matches: 12. Free-text hits: 15. Used: 5. Discarded: 22. Distinct channels in the used lane: 4.

The sweep ran case-sensitive entity tokens CME, CME Group and Chicago Mercantile Exchange, plus case-sensitive free-text patterns for the same, across all 51,928 distilled claims. The brief flagged CME as collision-prone and it was, in an unusual form.

DISCARD ONE — fourteen crypto claims that use CME as a measuring instrument, not a company. The free-text lane is dominated by Bitcoin market-structure claims that reference CME futures as a landmark: "closing the CME futures gap" (arthur_hayes, 2019-07-30); "pod shops and banks buy IBIT and short CME futures for basis yield" (arthur_hayes, three separate claims across 2025-12-01, 2025-12-04 and 2025-12-19); "CME Bitcoin futures open interest at ~$2.9B" (empire, 2023-07-07); "CME options open interest is at an all-time-high $6B" (anthony_pompliano_show, 2025-09-25); "whales spiked their buying" off the CME gap (anthony_pompliano, 2025-11-18); "CME margin hikes force leverage out of vertical moves" (compound_and_friends, 2025-12-30); "CME raising margins near-daily" on silver (andreas_steno, 2026-01-05); "the short-CME-futures/long-spot-ETF basis trade is delta-neutral" (natalie_brunell, 2025-03-13); and others. Every one is a view about Bitcoin, silver or market structure that happens to use CME's contracts as the reference instrument. None is a view on the company or the security. All fourteen are discarded. This is a subtler failure mode than the USB/Universal-Serial-Bus or CEG/Constellation-Software collisions: the string refers to the right company, but the claim is not about it.

DISCARD TWO, and it is a breadth problem rather than a relevance problem — EIGHT of the twelve entity claims are ONE PODCAST EPISODE. All eight business_breakdowns entity claims are dated 2025-08-17 and cover, in sequence, the clearing moat, non-fungibility, ~90% interest-rate-futures share, volatility as a volume driver, energy benchmarking, pricing power against tick size, 5-8% organic growth, and six-asset-class diversification. That is a single analysis distilled into eight records. Treating it as eight independent claims would inflate breadth by a factor of eight, and this programme has repeatedly found that inflated breadth is how a concentrated lane comes to look like a consensus. We collapse the eight to one and score the lane at breadth 4.

The five used claims (the collapsed block counted once), verbatim where quoted:

> 2025-08-17 · bullish · conviction 65-85 · channel: business_breakdowns · speaker: null · EIGHT RECORDS FROM ONE EPISODE, COLLAPSED TO ONE

> "CME is best-in-class derivatives exchange with dominant liquidity and vertically integrated clearing; a durable, high-quality compounder." · "Vertically integrated clearing plus non-fungibility of futures locks liquidity into CME's own products — a structural competitive advantage." · "CME holds ~90%+ share of US interest-rate futures; growing Treasury issuance and deficit-driven supply structurally lift long-term volumes." · "CME captures a tiny fraction of contract value versus tick size, giving latent, judiciously-used pricing power without hurting users." · "CME grows organic top line ~5-8% over time... ~$6B revenue, ~80% clearing/trading."

> 2026-06-23 · bullish · conviction 68 · horizon: thesis · entities: CME · channel: compound_and_friends · speaker: null

> "Exchange-stock selloff on perpetual-futures fears (CME biggest weekly drop since 2020, Cboe -8%, ICE) is way overdone; want to buy CME — it's the king."

> 2026-03-05 · tagged bullish, BEARISH ON CME · conviction 85 · SKILL 1.2 · entities: Hyperliquid, CME, ICE · channel: arthur_hayes · speaker: null

> "Perps' edge is clearing, not product spec: loser-can-only-lose-margin + ADL lets exchanges offer real leverage; guaranteed-settlement TradFi clearing can't compete."

> 2026-04-09 · neutral · conviction 80 · horizon: principle · channel: raoul_pal · speaker: null

> "Order books tend toward monopoly unless acted upon, but markets repeatedly demand a competitor — Nasdaq to NYSE, ICE to CME, Bullish to Deribit."

> 2022-09-12 · bullish · conviction 65 · entities: CME, Bitcoin · channel: real_vision · speaker: null

> "Price discovery demonstrably happens on regulated CME futures; industry has satisfied surveillance-sharing and manipulation concerns."

STANCE-TAG INVERSION — CONFIRMED AND CORRECTED. The arthur_hayes claim of 2026-03-05 carries stance: bullish because the entity it praises is Hyperliquid. Read against CME — which is in its entity list — it is the single most bearish claim in the lane, and it comes from the highest-skill voice in it (1.2). This is exactly the "stance tags are sometimes inverted relative to the named entity" defect the programme has catalogued, and a process that read the tag rather than the content would have scored the strongest bear as a bull, on a lane that is otherwise uniformly positive. We score it as bearish on CME.

Concentration test — RUN, and PASSES only after the collapse. Before collapsing the single-episode block, business_breakdowns supplies 8 of 12 entity claims — 67%, twice the threshold, and the lane would fail. After collapsing it to one analysis, the used lane draws on four channels — business_breakdowns, compound_and_friends, arthur_hayes and raoul_pal, plus real_vision — with no channel above 40%, and it passes. We report both results, because the pre-collapse figure is what a naive count would produce.

Attribution note. All five used claims carry speaker: null and are channel-attributed. No management voice appears. arthur_hayes operates a crypto derivatives venue and is therefore a commercially interested party with respect to the perpetual-futures question — the "chip-maker's CEO supplying a software lane" class. We do not exclude him: the argument is specific, mechanical and checkable, and it is the strongest bear case available. We flag the interest and weight the claim as an argument rather than as disinterested evidence.

Conclusion. Breadth 4, claim count 5, net conviction positive-moderate. The knowledge base is bullish on CME's moat, from one high-quality but single-source analysis; and it contains, from its highest-skill voice, a specific mechanical argument that the moat is being attacked — mis-tagged as bullish. That is a genuinely useful lane, and the debate inside it is the reason this dive is Tactical rather than Core.

6. Verdict, kill-criteria and flip conditions

Buy — Tactical.

The arithmetic. At $262.63 CME trades at 21.4x the FY2026 consensus of $12.254 and 20.3x FY2027's $12.924, having earned a 64.9% operating margin and a 62.0% net margin on fiscal-2025 revenue of $6,520.6M, with net cash of $666.2 million, interest coverage of 50.3x, and a 4.28% dividend. Our base fair value of $297 is 13.1% above spot with 1.75:1 price asymmetry and roughly 2.4:1 on total return. Roughly a quarter of the expected return is a dividend that requires nobody to change their mind — which is the structural feature that distinguishes this from a pure re-rating bet.

The entry. The stock is 19.6% below its 52-week high, 5.7% below its 200-day average, and has underperformed the S&P by 31 points over twelve months while operating income grew. Beta is 0.276, the lowest in this batch by a factor of two.

Why Tactical and not Core, stated as four reservations.

First, the competitive question is genuinely open and the evidence is two-sided. June-quarter average daily volume FELL 1% to 29,843 thousand contracts, with interest rates down 6% and energy down 13% — against six-month volume up 10%. The company's explanation (volatility normalising after an early-2026 Middle East spike) is plausible and unproven. The knowledge base's highest-skill voice argues that guaranteed-settlement clearing structurally cannot compete with the perpetual model, and that voice runs a competing venue.

Second, the base case requires modest multiple expansion. At 20.3x held flat the price is spot and the return is the 4.6% shareholder yield. We think the discount is a competition discount applied to a franchise whose position has not measurably changed, but that is a judgment, not arithmetic.

Third, the knowledge-base lane is one podcast episode plus four claims. Eight of the twelve entity records come from a single 2025-08-17 analysis; collapsed honestly, breadth is 4, not 12.

Fourth, sentiment is the most negative in this batch. Five of thirty-seven analysts have SELL ratings and the vendor consensus is "Hold", on a company with a 65% operating margin. And the payout ratio is 95.4%, so the dividend that carries a quarter of the return has no retained buffer.

Pre-registered KILL criteria — what would take this to Watch or Avoid. Most are volume and price metrics, because that is where competition appears:

Pre-registered UPGRADE conditions — what would take this to Buy — Core:

Where CME fits in the Synthos Framework Portfolio. The financials sleeve, entering at 1.5% today with a 3% target scaled on the 2026-10-28 volume disclosure. Sizing note: this is a low-beta (0.276), high-margin, net-cash business paying 4.28% while a single structural question resolves. The correct response is a position that collects the dividend and can be doubled on volume confirmation — not one that has to be defended if the October volume print is weak. Logged as a tracked Synthos call (Buy — Tactical) as of 2026-08-04 at $262.63, with the fair-value anchors, kill criteria and upgrade conditions all gradeable.

Single biggest risk: perpetual futures, and it is an attack on the moat rather than on the earnings. CME's entire competitive position rests on the fact that a futures position opened in its clearing house must be closed in its clearing house, and that the clearing house guarantees settlement. The perpetual model inverts that: a loser can only lose their posted margin, auto-deleveraging replaces the guarantee, and the venue can therefore offer leverage a regulated clearer cannot. The knowledge base's highest-skill voice states it directly — "guaranteed-settlement TradFi clearing can't compete" — and the market has taken 19.6% off the share price on the possibility. The evidence to date is genuinely mixed: six-month volume up 10%, June quarter down 1%, interest rates down 6% in a quarter the company says was simply calmer. We are siding with the disclosure and the margin structure over the narrative, at a price that already contains roughly five multiple points of discount, while collecting 4.28% — and the kill criteria above are all volume and price metrics because the chart will not warn about share loss until it has happened.

Provenance & disclosures